Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
China Resources Double-Crane Pharmaceutical Co PS Ratio Related Terms
China Resources Double-Crane Pharmaceutical Co PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co PS Ratio Chart
China Resources Double-Crane Pharmaceutical Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Double-Crane Pharmaceutical Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Resources Double-Crane Pharmaceutical Co PS Ratio vs Drug Manufacturers Industry
China Resources Double-Crane Pharmaceutical Co PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
China Resources Double-Crane Pharmaceutical Co's Share Price of today is ¥16.93. China Resources Double-Crane Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥10.36.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) has a PS Ratio of 1.63 as of Jul. 19, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. This is near median its historical median of 1.76. Over the past decade, China Resources Double-Crane Pharmaceutical Co's PS Ratio has ranged from 1.29 to 3.83. According to the industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #367 out of 954 companies in the Drug Manufacturers industry, placing it in the top 38.5%.
Is China Resources Double-Crane Pharmaceutical Co's PS Ratio too high?
China Resources Double-Crane Pharmaceutical Co's current PS Ratio of 1.63 is near median its 10-year median of 1.76. Over the past 10 years, this metric has ranged from a low of 1.29 to a high of 3.83. The Drug Manufacturers industry median PS Ratio is 2.32. China Resources Double-Crane Pharmaceutical Co's value of 1.63 is 29.7% below this industry median. Based on the distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #367 out of 954 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, China Resources Double-Crane Pharmaceutical Co has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does China Resources Double-Crane Pharmaceutical Co's PS Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, China Resources Double-Crane Pharmaceutical Co ranks #367 out of 954 companies for PS Ratio. This puts China Resources Double-Crane Pharmaceutical Co in the upper half of its industry. The industry median PS Ratio is 2.32. China Resources Double-Crane Pharmaceutical Co's value of 1.63 is 29.7% below this benchmark. Historically, China Resources Double-Crane Pharmaceutical Co's own PS Ratio has ranged from 1.29 to 3.83 over the past decade. While the company's 10-year median is 1.76 vs. the industry median of 2.32, China Resources Double-Crane Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Drug Manufacturers company?
The median PS Ratio among Drug Manufacturers companies is 2.32, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Resources Double-Crane Pharmaceutical Co's current PS Ratio of 1.63 is 29.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median PS Ratio is 2.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Resources Double-Crane Pharmaceutical Co's current PS Ratio is 1.63, which is near median its own 10-year median of 1.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Double-Crane Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co (SHSE:600062) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.81, compared to a current price of ¥16.93 — trading 10% below its estimated fair value. The current PS Ratio is 1.63, which is near median its 10-year median of 1.76 and 29.7% below the Drug Manufacturers industry median of 2.32. China Resources Double-Crane Pharmaceutical Co's overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For China Resources Double-Crane Pharmaceutical Co (SHSE:600062), the current PS Ratio is 1.63 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥16.93 is trading 10% below its estimated GF Value™ of ¥18.81.
GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:600062:
PS Ratio: 1.63 (near median its 10-year median of 1.76)
GF Value™: ¥18.81 vs. price of ¥16.93 (10% below fair value)
Industry Position: 29.7% below the Drug Manufacturers median (#367 of 954)
No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Double-Crane Pharmaceutical Co Business Description
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
90GF Score
Get the complete analysis for SHSE:600062
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600062 has been successfully added to your 
